the novavax, 60%. astrazeneca, not so good. of note, pfizer did a small study in which they looked at the effect in south africa and found that, as a matter of fact, it was 100% effective. the caveat here is it is still a very small study. but note the j&j, even though it was 64% effective in south african study, there were virtually no deaths or hospitalizations. so although the efficacy went down for moderate disease, there was good protection against serious disease. then we have the p.1 -- the p.1, right now ravaging brazil. we know there is a variable protection and real-world effectiveness, namely things that were not done necessarily in the clinical trial. in brazil, it was 50% fictive after a single dose. they went on to a second dose, and that stayed at approximately 50%. this was under the condition with a 5% of the cases with p.1. similar results from chile. a little bit better with 67 percent effective disease 14 days after the second dose. next slide. returning to the united states, the california variant, 429.427.

novavax, nicely placed in the middle. matt: thank. medical group to with a look at your stock -- read ago grouped with your stock of the hour. bitcoins soars to an all-time high. just one day ahead of the highly anticipated coinbase listing. we are seeing bitcoin up, for we were seeing bitcoin up over $63,000. i will pull it up myself real quick and take a look. the question is, is interest in coinbase that is boosting bitcoin, we were asking yesterday, if coinbase would suck some flows out of the crypto space? it is pretty fascinating to watch. we will dig into the details with president and founder of the chamber of digital commerce. this is bloomberg. ♪ want your workout to be easier, more effective, and more convenient? then you should try aerotrainer by golo. the new full body workout that you can do at home or anywhere. it's great for planks, squats, core, and glutes. you'll strengthen and tone muscles, relieve back pain, and reduce stress. it's also great for yoga and pilates. get noticeable results in just ten minutes a day. (

the problem is right now, we have to make sure we have other vaccines like novavax and others coming on, probably. and i think we will be in the position to be able to share vaccines as well as know-how with other countries who are in real need. that is the hope and expectation. and i might add, when we were in a bind at the beginning, india helped us. thank you. >> sir, what did you ask of the vice president to do to address the skepticism. >> what do you say to those who are still hesitant? >> thank you. >>, thank you, sir. -- >> thank you, sir. [indiscernible chatter] >> hi, there. welcome to the cato forum today on infrastructure. i am chris edwards, an economist at the cato institute. i have written much over the years on the

the problem is right now, we have to make sure we have other vaccines like novavax and others coming on. i think we will be in the position to be able to share vaccines as well as know-how with other countries who are in real need. that is the hope and expectation. i might add, when we were in a bind at the beginning, india helped us. thank you. [indiscernible] [indiscernible chatter] >> as he approaches his 100th day in office, president biden will give his first address to a joint session of congress wednesday night. our live coverage begins at 8 p.m. eastern. >> a special representative for afghanistan reconciliation and a former u.s. ambassador to the u.n. testifies this afternoon before the senate foreign relations committee. that begins today at 2:30 p.m. eastern time on c-span. he is the u.s. programs director of research at the migration policy institute. he is here to talk about refugee policy. what is the official policy of letting refugees into the u.s. right now? guest: officially, the policy is if someone has been persecuted against or fears persecution due to race, nati

the problem is right now, we have to make sure we have other vaccines like novavax and others coming on, probably. and i think we will be in the position to be able to share vaccines as well as know-how with other countries who are in real need. that is the hope and expectation. and i might add, when we were in a bind at the beginning, india helped us. thank you. >> sir, what did you ask of the vice president to do to address the skepticism. >> what do you say to those who are still hesitant? >> thank you. >>, thank you, sir. -- >> thank you, sir. [indiscernible chatter] >> as he approaches his 100th day in office, president biden will give an address to a joint session of congress. our coverage begins at 8:00 p.m. eastern with the address at 9:00 p.m. eastern. listen live with the c-span radio app. ♪ >> next, senate commerce subcommittee hearing on protecting consumers from scams during the pandemic. this one is an hour and a half.

the problem is right now, we have to make sure we have other vaccines like novavax and others coming on, probably. and i think we will be in the position to be able to share vaccines as well as know-how with other countries who are in real need. that is the hope and expectation. and i might add, when we were in a bind at the beginning, india helped us. thank you. >> sir, what did you ask of the vice president to do to address the skepticism. >> what do you say to those who are still hesitant? >> thank you. >>, thank you, sir. -- >> thank you, sir. [indiscernible chatter] announcer: as he approaches his 100th day in office, president biden will give a joint address to congress wednesday night beginning at 8:00 p.m. eastern, with the address at 9:00 p.m. eastern on c-span, c-span.org, or live on the c-span radio app. ♪ [fireworks] ♪ announcer: on monday, the u.s. census bureau released the results from the 2020 census, revealing the population, shifts in population, causing some to gain or lose a seat in the u.s. house of representatives. for more, we spoke to reporter on "washington j

the novavax 60%. the astrazeneca is not so good. of, note pfizer did a small study in which they looked at the effect on south africa and they found that as a matter of fact, it was 100 percent effective. the caveat here is still a very small study. the j and j even though it was 64% effective in south african study there were virtually no deaths or hospitalizations. although the efficacy went don't for moderate disease, there was good protection against serious disease. next slide. then we have the p1, the one right now ravaging brazil. we know from studies now that there is variable protection in real world effectiveness. namely things that were not done necessarily in clinical trial. in brazil, it was 50% effective after a single dose. they went to a -- dose and this was approximately 50 percent. rather similar results from chile. a little bit better with 61% effective rather than symptomatic disease 14 days after the second dose. next slide. not returning to the united states. the california variant, 429 427. next slide. here we

their second dose could be the same again or a shot of moderna or novavax.helle roberts has more. currently the nhs offers people an identical covid—19 vaccination for their first and second doses. but some experts believe switching to a different brand of vaccine for the second may give a broader and longer lasting protection against the pandemic virus and new variants of it as well as more flexibility in the vaccine rollout. more than 800 people have been helping researchers investigate is in a trial. they received two doses of either pfizer, astrazeneca or a combination of both to see which works best for immunity. results from the first stage are expected next month but the investigators now hope to recruit around 1000 people aged 50 or older to take part and test more vaccines in different combinations. that includes the new moderna vaccine and the novavax one expected to be approved soon in the uk. those with one and — approved soon in the uk. those with one and then _ approved soon in the uk. those with one and then with - approved soon in the uk. tho

two more vaccines are being assessed by the regulator the mhra — novavax, where there are 60 millionder, and janssen, 30 million doses. trials are ongoing with other vaccines where the government has made preliminary orders. so will confidence in the oxford—az vaccine be affected? people in younger age groups we spoke to had varying opinions. i am a bit concerned to hear it, because i'm 2a and i've already had my first dose of the astrazeneca vaccine, and i have my second dose booked in for a couple of weeks. it's one of those very rare cases. but it might happen, but it probably won't. the risk is probably... it's probably worth the risk, right? i'm still all for it. i'm going to do a little bitl more research now into it, but i still think at- this point i would get the astrazeneca vaccine. it remains to be seen how people react to today's announcement, so one leading official made the point that the chance of getting a blood clot to having covid—19 was much higher than with the az vaccine. hugh pym, bbc news. now on bbc news — our world. hadicha is fighting forjustice. her husband

the problem is right now we have to make sure we have other vaccines like november novavax and others to oil and i think we'll be able to share vaccines as well as know-how with other countries who are in real need that's the hope and expectation. i might add when we were in a bind in the very beginning, india helped us. thank you. >>> all right. there is president biden after repeating the news out earlier today, kellie, that americas are free to go outside in small groups and do so maskless. he and the cdc still suggests wearing a mask in large groups, so you would have to say that's progress meg tirrell, wrap what we just heard. >> the president answering the question, he was asked why was he still wearing the may have been give the guidance, and he said watch me put this mask away and not put it back on until i get back inside. for people who are fully vaccinated if you're outdoors, not in a crowd, you don't have to worry about wearing a mask. they are trying to provide incentives for people to go out and get vaccinated particularly for seniors, 68% of seniors in the u.s. fully va

but when novavax first him out there was a concern about anaphylaxis, and allergic reaction that occurredn rare cases. i think it is clear that those vaccines are related to anaphylaxis, there is a very small risk of fact. and that can be fatal. people die of bee stings all the time, for example. they have a reaction to penicillin. but we understand how to manage it. we have observed people for a. of time and the risk is managed. everybody is fine with that now. i think what we need is some kind of understanding of, ok, now we know the risk for this clotting syndrome is extremely rare. one and one million people -- one in one million people. maybe they will find more people , maybe three and one million but probably not much greater. you don't want people to die. so you have to come up with a mitigation measure, a prevention measure, there could be certain populations in which you monitor them from 2-4 weeks after they receive the vaccine and after that they will probably be fine. these vaccines are extremely well monitored. the people who get them are being watched very carefully. i just

the novavax vaccine also did well. has not been authorized for use in the united states however.esearchers did not test pfizer's vaccine. >>> the vaccine roll out in the bay area raised concerns about equity when some of the communities with the highest infection rates were having trouble getting the vaccines. one group that was seemingly invisible throughout is home bound seniors who were able to go out to those vaccination sites. forgotten no more, a vaccinate program got under way in the peninsula. david louis shows us how nurses are making those elderly cry tears of joy. >> reporter: this team is on a mission. they're going out with a vile of vaccines to go out to inoculate seniors who are the most in need. >> these are people who have is not been able to get vaccines yet. and they're very vulnerable because that's why they're home and home bound. >> reporter: the six patients to be visited range in age from 85 to 99. they were identified by programs such as meals on wheels who recognize their isolation. home visits go much slower than a mass vaccination event. >> given it to

specifically, novavax up more than 8%. but what does this all mean? you know, are there other areas where you can pounce in and start scooping up shares that are either advantage signs or vaccine -- vaccines or vaccine related? to our floor trade thers, tom hayes and chris. chris, j&j's 1.3% cheaper. now's the time to buy? what do you think? >> i think absolutely. when you think about the magnitude of what's happening here, we have 6 cases out of over 6 million doses. you want to be very careful about that, you want to make sure that if there are important protocols to put in place, to understand maybe people that may be at more risk than others, you want to do that. but it's not going to affect the overall efficacy, and in the long run, covid's going to to be with us for a while. so i think it's a steal. liz: you think it's a tale here. let -- steal here. let me get to tom. there's a massive biosphere of companies related to the making and distribution of vaccines. where would you pulse your money even as we see -- put your money right now even as we

it's also good to know novavax, another vaccine distributor, might be submitting their data at some pointonal trials that were very promising so another thing that might be on our horizon is there may be other producers, including novavax, as well as astrazeneca. oh, and to your point about the -- >> yeah, please, go ahead. >> to your point about the need for a global governance and equity, listen, for the very reasons that we're rushing to vaccinate everybody here, i think it's equally important for us to try to get a global vaccine equity because if we only vaccinated people here, you might see the virus continue to mutate in other parts of the world since we're globally connected, it would make us vulnerable again. that's one of the reasons why we need that effort >> so the other piece of news we saw yesterday that frankly seemed so incredibly promising to me as a parent, pfizer said that their vaccine is 100% effective for kids between the ages of 12 and 15. what does that mean for getting kids back into the classroom in the fall and the timeline for getting younger kids vaccinated? >

the novavax vaccine also did well. has not been authorized for use in the united states however. did not test pfizer's vaccine. >>> the vaccine roll out in the bay area raised concerns about equity when some of the communities with the highest infection rates were having trouble getting the vaccines. one group that was seemingly invisible throughout is home bound seniors who were able to go out to those vaccination sites. forgotten no more, a vaccinate program got under way in the peninsula. david louis shows us how nurses are making those elderly cry tears of joy. >> reporter: this team is on a mission. they're going out with a vile of vaccines to go out to inoculate seniors who are the most in need. >> these are people who have is not been able to get vaccines yet. and they're very vulnerable because that's why they're home and home bound. >> reporter: the six patients to be visited range in age from 85 to 99. they were identified by programs such as meals on wheels who recognize their isolation. home visits go much slower than a mass vaccination event. >> given it to have pfiz

it has been shown in a number of vaccine studies, including j&j, novavax and astrazeneca that those vaccines are less effective against preventing infection with the south africa strain. the vaccines are excellent at preventing severe disease and are effective against severe disease from the south africa variant. >> we're getting a new report from the university of minnesota, epidemiologists are saying that children may be spreading the variants more than we first thought. >> i don't know that we have the data yet from our cases to make comments on that. our case rate, another good thing in the bay area, is relatively low. even though we are finding the variants, overall, we're not seeing a lot of cases. >> that makes sense. i'm just scrolling through our questions here. and i'm curious to get your thoughts on this. if there's going to be a fourth wave, a new virus, are we going to have a fourth lockdown? i think governor newsom says we have the lowest positivity rate in the country now. so that's good news. >> that is good news. and at stanford our positivity rate was 2% so very low. i thin

he mentioned novavax. the stock is up 18 points.ot sure how much he was supposed to say about that. art, obviously covid is one of the things hanging over this market for some time but as you see the cdc loosening up their restraints, at least their guidelines. if you saw tall daigh talladega, a lot of it reopened and on the move. what is holding the market back? >> you bring up a really good point. what is holding the market back, we're in earnings season that forces investors take a wait-and-see attitude. once we get through this week the heaviest of the earnings reports, we're likely justified where we've gotten both company stocks and indexes too the investors will take another run at things because earnings estimates have gone higher for the second quarter and for the balance of this year and we're only about a third of the way through the earnings reporting season. if you end earnings season at all-time highs, not hard for investors to have a wait-and-see mode. i think that is where we are. charles: you kind of wonder how much

the problem is, right now, we have to make sure we have other vaccines like novavax and others comingthink we will be in a position to be able to share vaccines, as well as know-how. with other countries who are in real need. that is the hope and expectation. i might add, when we are in a bind at the beginning, india helped us. >> in a few minutes on outside source, we will bring you our next video and a series looking the promises made before brexit and look yet was happening now in the reality. ♪ >> nothing, it seemed, was too big to withstand the force the tornado. the extent of the devastation will lead to renewed cause for government help and housing. >> internationally, there have already been processed. they received no warning of the accident, the rusans first denied anything had gone wrong. activity levels began to increase outside russia, then they were forced to admit the accident. ♪ >> the mood here is of great celebration. this is the end of a 12 year war, they have taken the a than fighting for for so long. >> 7:00 in the morning, the day when power began to fast -- to p

the problem is, right now we have to make sure we have other vaccines like novavax and others coming on, probably, and i think we'll be in a position to be able to share, to share vaccines as well as know-how with other countries who are in real need. that's the hope and expectation. i might add, when we were in a mind in the very beginning, india helped us. >> reporter: what did you ask the vice president to do to help with vaccine skepticism -- >>> president biden taking a few more questions, but his whole point there and part of the point he's making right now as he walks back into the white house not wearing a mask. he wants to make the point that the cdc's new guidance that fully vaccinated people can go maskless outdoors as long as they're not in big crowds. and the other part of the message, there's never been a better time and perhaps a better reason to get vaccinated again because we're beginning to see more freedom for those individuals who have been fully vaccinated. let's go to chief white house correspondent kristen welker who is there for us with more on what we just he

the novavax -- the caveat here is still a very small study.ut note, the j&j, that even though it was 64% effective in south african study, there were virtually no deaths or hospitalizations. so although the efficacy went down for moderate disease it was good protection against serious disease. next slide. then we have the p.1, the one that is right now ravaging brazil. next slide. we know from studies now that there's variable protection in real world effectiveness, namely things that were not done necessarily in a clinical trial. in brazil it was 50% effective after a single dose. they went on to a second dose and that stayed at approximately 50%. this was under the condition where 75% of the cases were p.1. rather similar results from chile, a little bit better with 67% effective versus symptomatic disease, 14 days after the second dose. next slide. now turning to the united states, the california variant 429/427. here we have in vitro data. we take the antibodies induced by vaccines, in this case mrna and we determine their ability to neutr

. >> o'donnell: she's one of the lead vaccine scientists at novavax, a maryland biotech company currently in the finalal tr trials of its covid vaccine. the team isn't just led by a woman-- it's almost all women.sa do you see a difference in the way a team of female scientists work together? >> they communicate. they get along very well. i never see them stress out. >> reporter: patel isn't alone. women are leading the effort at pfizer, johnson & johnson, and oxford-astrazeneca. and at n.i.h., kizzmekia corbett helped design the moderna shot. >> actually, i was told i was one of the first people to open the vial of the vaccine. >> reporter: patel has a theory as to why women are at the forefront. >> we have a power inside us. we are very goal-oriented, very persistent in achieving that goal. >> o'donnell: why do you think science is such a good field for women? >> oh, science is fun. you know, there is no boundary. it's all unlimited space. >> o'donnell: before the pandemic, the number of women ie science and engineering was rising, up 36% over the past decade. but a new study says women

they have procured so much of the two mnra vaccines in abundance and there is the novavax particle vaccinehen you look at ace sub—saharan africa for latin american countries, they are all pretty much adenovirus vector vaccines, and if someone signals a problem or sounds an alarm, that could have really devastating effects on the ability of african and latin american countries to fight this pandemic. so it is so important, how we operate, how we proceed, and how we not only think about the safety of the american people but think about the world at this point. demonstrators have filled the streets for the third st note of protest as authorities declared the situation and unlawful assembly. declared the situation and unlawfulassembly. here declared the situation and unlawful assembly. here are the latest pictures from around minneapolis. three marles away. the white policewoman who shot the 20—year—old black man on saturday resigned from the police force, as has the police chief of brooklyn centre, the town where it actually happened eight we will stay with these pictures of what happened on

two more vaccines are being assessed by the regulator the mhra — novavax, where there are 60 million30 million doses. trials are ongoing with other vaccines where the government has made preliminary orders. so will confidence in the oxford—az vaccine be affected? people in younger age groups we spoke to had varying opinions. i am a bit concerned to hear it, because i'm 2a and i've already had my first dose of the astrazeneca vaccine, and i have my second dose booked in for a couple of weeks. it's one of those very rare cases. it might happen, but it probably won't. the risk is probably... it's probably worth the risk, right? i'm still all for it. i'm going to do a little bit more research now into it, _ but i still think at this point - i would get the astrazeneca vaccine. it remains to be seen how people react to today's announcement, so one leading official made the point that the chance of getting a blood clot through having covid—19 was much higher than with the az vaccine. hugh pym, bbc news. let's take a look at the latest government coronavirus figures. there were 2,763 new co

novavax and the others should follow suit. —— serum institut.ormal times we would say yes, this is essential and people want to have value on their investment. in times of the pandemic, we have to modify this somewhat to give greater access. eitherwe this somewhat to give greater access. either we manufacture in volumes that will serve everybody, or we have a situation in which you are willing to transfer the know—how. if they give it on a voluntary basis, this would not arise. so, how do we encourage more of that, now that people are dying? and then we can have are dying? and then we can have a agreement for dealing with outbreaks in the future. the director-general _ outbreaks in the future. the director-general of - outbreaks in the future. the director—general of the world trade organization, doctor ngozi 0konjo—iweala, speaking to faisal islam there. president biden has unveiled an infrastructure investment plan on a scale not seen in the united states in decades. the $2 trillion package aims to modernise roads, repair bridges and promote c

novavax, j&j, and all the others should follow suit. it's valid to have people want a return on their investment. i think during public times of pandemics, we have to modify this somewhat to give greater access. either we manufacture in volumes that will serve everybody, if you are the one that has the patent, or have a situation in which you are willing to transfer the know—how. and in fact, if they did it on a voluntary basis, this would not even arise. so, how do we encourage more of that, now that people are dying? and then we can have a framework agreement for dealing with outbreaks in the future. the new director—general of the world trade organization, doctor ngozi 0konjo—iweala, speaking to faisal islam there. time for all the sport now. hello, i'm gavin ramjaun and this is the latest from the bbc sports centre. we start with news of a shock defeat for germany as they lost a world cup qualifier for the first time in 20 years. they were beaten 2—1 at home by north macedonia. the visitors took the lead in first—half stoppage time

novavax, where there are 60 million doses on order, and janssen, 30 million doses.ment has made preliminary orders. so will confidence in the oxford—astrazeneca vaccine be affected? people in younger age groups we spoke to had varying opinions. i am a bit concerned to hear it because i'm 2a and i've already had my first dose of the astrazeneca vaccine. and i have my second dose booked in for a couple of weeks. it's one of those very rare cases. but it might happen, but it probably won't. the risk is probably, it's probably worth the risk, right? i'm still all for it. i'm going to do a little bit more research now into it, _ but i still think at this point - i would get the astrazeneca vaccine. officials say the benefits outweigh the risks for the vast majority of adults. it remains to be seen how people react. hugh pym, bbc news. 0ur political correspondent damian grammaticas is in westminsterfor us. we have just heard we havejust heard boris we have just heard borisjohnson speaking. it's a we havejust heard borisjohnson speaking. it's a reminder we have just heard

the problem is, right now, we have to make sure we have other vaccines like novavax and others coming we will be in a position to be able to share, to share vaccines as well as know—how with other countries who are in real need. that's the hope and expectation. and i might add, when we were in a bind at the very beginning, and he helped us. thank you. beginning, and he helped us. thank ou. �* . , �* you. and with that, president biden heads along — you. and with that, president biden heads along the _ you. and with that, president biden heads along the path _ you. and with that, president biden heads along the path and _ you. and with that, president biden heads along the path and heads - heads along the path and heads inside. let's bring in the bbc�*s gary o'donoghue, live from washington. i picked out two main messages there, a shift in the rules around wearing masks and also an emphasis on people who have not been vaccinated soon. i emphasis on people who have not been vaccinated soon.— vaccinated soon. i think that's a lot apart. _ vaccinated soon. i think that's a lot apart, perh

we really do need a website for every single vaccine, j&j, pfizer, astrazeneca, sinovac's, and novavaxy get it. i take your points, it is difficult for countries and people like yourself with your family who are worried about side effects, but we do not have any evaluation of the side effects at the moment. however, i cannot imagine that china would want to roll out a vaccine, given that they are using this as diplomacy to then roll it out and have enormous numbers of adverse events. yes, it would be better to see the data. shery: before you go, how confident are you that these travel bubbles will go ahead and go successfully, given that we are dealing with uneven levels of immunity and vaccination with the countries that are involved? >> good point. you really have to have the travel bubbles opened when most of the population has been vaccinated and have their full vaccination, so for the moment, the travel bubble for australia and new zealand can go ahead because we both got no circulation even if we got the one or two people to acquire it. for australia/new zealand, that risk is aro

that includes the new moderna vaccine and the novavax jab that is expected to be approved soon for useplications for what might lie ahead. we will be able to potentially use different vaccines for booster campaigns in the autumn and in fact mixed schedules may, and this is a big may, but they may give better longer term protection and that would be very interesting to see. so very exciting stuff. the study will run for a year but the first results should be available byjune orjuly and they will shape how the uk and the world continues to protect populations against this deadly virus. dominic hughes, bbc news. our medical editor fergus walsh is here. lets start with that trial we were hearing about, the interesting idea that you might be able to have one dose from one brand at the second from another. tell us more about that trial and why it is important to. i that trial and why it is important to. ~ , that trial and why it is important to. ~' , ., to. i think it is important because if ou can to. i think it is important because if you can mix _ to. i think it is important because if yo

that has been expanded to include the moderna and novavax vaccines.e volunteers are needed for the trial, the comcov trial, people can sign up online, and the first results should come next month, with more in the summer. it's a controvsersial issue — and now the government is launching a consultation into whether care home staff in england should be required to get a coronavirus vaccine. it's now a year since care homes were struggling to cope with the peak of the first wave. april 12th 2020 saw a95 deaths of care home residents from covid alone. a further 800—plus residents died from other causes. those combined figures were more than three times the number who died in total — from other causes — on the same day in 2019. many families and care providers argue that only a public inquiry will explain why residents weren't better protected. here's our social affairs correspondent, alison holt. this is david's way of seeing more of his wife, anthea. he volunteers as a gardener at her care home. hello, sweetheart. hello! snatched moments at the window ke

there is genetic immunization such as dna and rna, viral vectors, protein, such as novavax, and a number of others shown on the right hand part of the slide. next slide. with regard to the mrna vaccine, this work started a decade and a half ago when two people were working on rna and were able to modify the molecule to include a key inflammatory component that would have made use of the vaccine impossible. this led to the use of mrna as a platform. next slide. with regard to the virus, the one used by j&j, the nih has been funding for decades a highly skilled and accomplished person from harvard medical school who had been working on this for a considerable time and demonstrated how immunogenic this particular vector would be. next slide. then you get to immunogen design -- really the most fascinating component of this story, and it goes to a different discipline. next slide. and that is the crystallography and capability of investigators throughout the country who are working to get the right confirmation of the hiv envelope trimer -- nothing to do with coronavirus. they were using thes

process of doing something that might result in a product by the end of the year, and the product from novavax coming up. but at the end of the day, if mrna vaccines are the only ones we are going to be using, then you are going to end up with a bottleneck, so that is certainly true. alix: cure back -- curevac partaking variants into accounts -- curevac are taking variants into account with their trials. what do you expect? sam: all things being equal, you never know with vaccines. but given that pfizer/biontech and moderna both came out with similar efficacy levels, it would be a surprise if curevac came out with a different or much lower efficacy level. but let's not forget, the vaccine is being tested at a time where infection rates are different, where different strains are running year-round, and you have also got -- running around, and you've got it situation where the technology might be different. if we come in in the 75%, 80% range, that would be a homerun. alix:d to catch up. always good to talk to you, sam fazeli of bloomberg intelligence. for more on vaccine delays and what they me

and down the line, on johnson & johnson and novavax should those be approved in the uk. with the rollout here. how long will it be before we can see a widespread distribution for vaccines that can target just about everybody who wants to get one in the united kingdom >> reporter: here in the uk, the vaccine rollout has been billed as a key success of the u.s. government and boris johnson saying we will be on track still to provide every adult who wants one, a vaccine by the end of july as i mentioned, this does put more reliance on the pfizer and moderna vaccines coming through from the supply perspective. it puts more price on the nhs which has been operating on the basis of offering any vaccine to any person now because of the guidance, they have to reserve those doses for the younger crowd and give the astrazeneca vaccine to those above 30 years old a different story in the eu. in terms of the countries and reaction to the ema decision yesterday, it hasn't been a unified response we have the italian health authority and spain limiting the vaccine to those aged 30 and

looking at what he says is the back part of the year for a mass rollout, with additional and pfizer and novavaxoses to be secured by than. shery: it will also allow additional australians to quarantine at home, but this comes with fresh risks. paul: it does. the prime minister calls this the next sensible step to allow returning australians to quarantine at home. that would free up spaces in the hotel currency system. get more students and skilled workers into the country. he says returning australians would need to be vaccinated before they would be eligible for that. but state leaders are not so keen. there will be medical advice presented on this because we have had three new cases of a family of returned travelers catching the virus while in the hotel quarantine from other travelers were on the same floor. so it is pretty clear there is still some shortcomings remaining with the hotel quarantine system, and is concerned that things could eat -- things could get even more lax under home quarantine. but there is no home quarantine today however for travelers between australia and new zealand.

i pose that plateauing issue to mike novavax of galaxy digital and he made the point that you made justow, that it is still doubled this year. so, is it where it should be? well, what does that do for trading, the trading in the first three months of the year? that has fueled the revenue we are seeing. emily: we will hear more from your interview this hour. when it comes to the coinbase direct listing, what are you watching, what are you hearing from investors about how excited they are? yes, coinbase is making a lot of money, but this is an unproven market and we don't know where this is going. sonali: the other thing about it too, you and i spoke to the ceo last week. they are not the only game in town. they are going public at the high valuation, or do you invest in something else? these are real question marks right now. we will see, is it a direct listing, emily, that is the other thing exciting about this listing. the first real one on the nasdaq, first major technology listing on the nasdaq, a direct listing. it's just a matter of the love of the game to look at how much they wer

you have got novavax coming, johnson & johnson coming at some point.ot to go and take the vaccine shots, then it's going to have to slow things down. manus: sam, thank you very much. sam fazeli on the very latest on the vaccine front around the world. our senior pharmaceuticals analyst and director of research for emea. thank you for joining us both. steven major has been listening to that narrative. he is the global head of fixed-income research at hsbc. apart from the fact that i now sound old talking about young people under 30 want you to take vaccines but we will partner that -- wanting to take vaccines but we will park that. what is the most important thing here? the vaccine rollout and getting to grips with herd immunity by the end of july or is it the fiscal livery -- delivery? what is the most important thing, in your mind? steven: there is no doubt that the virus backdrop is not good for the eurozone economy and it is definitely dragon. you can see it in the -- dragging. you can see it in the data really. the main reason for higher yields in

more than one billion doses would come from the serum institute in india, from both astrazeneca and novavaxlance that with a population of 1.3 billion puts india in a difficult position to balance those needs. maryam: how disastrous could this be for africa? we are talking about some of the world's poorest countries. countries in africa want to vaccinate 35% of their population by the end of the year. that is not going to happen if astrazeneca doses produced by the serum institute are taken over by the indian government. guest: yes, we need to think about other contingencies. some of the good news is we are starting to see increases in manufacturing capacity of the mrna platform vaccines. with pfizer and biontech saying they can get to 2.5 billion doses this year, hopefully that is a significant uptick through covax. trying to understand how we can ramp up manufacturing capacity in other low and middle income countries will be important in the new few months. maryam: what are your thoughts on the indian government's involvement in vaccine shipments? guest: i think we are seeing this similar

we have the novavax vaccine coming along.make a different decision than a country entirely dependent on adenovirus vaccines. it will be risk versus benefit. the other problem is this not happening in a vacuum. it is happening in the background of a very aggressive anti-vaccine lobby that is piling on. that could easily derail a lot of efforts. i am particularly concerned about african and latin american country which backed themselves into a corner in the sense they became totally dependent on these adenovirus vectors vaccines in some cases. this is also true of the russian vaccine. we do not have any information about that. the impact, especially on the world slow and middle income countries could be devastating and i'm upset about what is going on. lisa: this is where i wanted to go. the communication of some of the details as we learn about potential side effects you think the fda, the cdc, the european health officials should have waited before disclosing this information already think it is important to shore up the feel

not only has moderna, pfizer, and j&j, but also vaccines from novavax and astrazeneca. those could be made available and it would make a big difference in terms of the supply to the world. host: that from "face the nation." marlene, vaccine passports, what's your view? caller: i oppose it. i believe that text message from steve, who said we don't even have to show proof to vote, which really bothers me. everyone should have to show a license. but as far as this vaccine goes, no. if we aren't going to do it for voting, we shouldn't have to do it for the vaccine either. host: this is from jersey girl in pennsylvania saying she's undecided. what is the proposed timeline? we are in states where we will not have a chance to be vaccinated until late spring or early summer. this comes into play after all of us have had the opportunity for vaccination, then yes. athens, georgia, good morning. caller: i want to start out first, steve, thanks to our steadfast leader brian lamb. steve, we work rallying behind you after the incident. i don't usually call, how much do i love c-span,

that includes the new moderna vaccine and the novavax one that's expected to be approved soon in theone, then dosing with the other. and that would give a lot more flexibility if there was any problems with supply for one vaccine, for example, or changes in recommendations for different age groups. then if someone�*s been primed with one vaccine, they're not locked into getting the same vaccine for the second dose. and we will be testing those combinations against the new variants as they come through. so the blood tests we obtained, we'll test them against the new variants to see potentially if they offer any broader protection against the multiple different strains. volunteers need to have already had one covid jab on the nhs in the past few months and be willing to travel to a regional nhs hospital trust site in england to take part. they'll have blood taken to check how well vaccines trigger an immune response. the study will run for a year, but there should be some reportable findings byjune orjuly to shape how the uk and the world continues to protect populations against this d

novavax moving higher by a percent, astrazeneca down two-thirds of a percent.ficially hit 150 million vaccination shots given in the first 75 days of his administration. but what is important here, as we are awaiting the president, is that there will be, according to the administration, no more need by april 16th for you to check your state and local web sites of government to find out if you are, indeed, eligible. because coming april 16th everybody 16 and older will be eligible to get it. we've got a slight move downward for most of these names, regeneron, bill idea sciences, amgen, they had a roll-in or developed all of these vaccines. i want to quickly check pfizer, move, yeah, slightly lower by two-thirds of a percent. moderna up 2.5%, j&j down a quarter of a percent. and, again, we want to make this clear, the moving up of the vaccine eligibility rate for all adults starting 16 -- i know 16-year-olds are not exactly adults, but 16 and over by two weeks. we'll be watching very closely how this affects the u.s. economy. we do understand that he will also sa

the novavax vaccine also did well but that vaccine has not been authorized in the u.s.. researchers did not test pfizer 's vaccine. >>> california's top epidemiologists are cautiously optimistic that there will avoid a fourth wave but they say the next two weeks are critical in stopping the slow rise in cases. every bay area county is showing a small increase in cases over the past week. in most regions, that is a rise of a fraction of a percent. only napa and solano counties maxalt transmission rates over 2%. >> there is 2500 cases a day in california. we want it to be at zero. >> the next two weeks are critical as the state is between vaccine shipments. they are hopeful more vaccines and the easing of eligibility restrictions can stop a fourth wave. >>> we've got a broken deck of clouds over most of our neighborhoods and that is the same on the peninsula where 51 in san bruno is the warm spot. 38 in menlo park. redwood city, 41. everybody else in the upper 40s. there is a touch of a breeze and a wind chill. temperatures mainly in the mid- 40s to around 50. without the

the problem is right now we have to make sure we have other vaccines like novavax and others coming on probably. and i think we'll be in a position to be able to share -- to share vaccines as well as know how with other countries who are in real need. that's the hope and expectation. and i might add, when we were in a bind in the very beginning, india helped us. thank you. >> what did you ask the vice president to do to help with vaccine hesitancy. >> you've been watching president biden touting what he calls stunning progress in the fight against the coronavirus pandemic. his administration making a new push for americans who have not yet gotten vaccinated to do so. and the cdc unveiling the new guidelines for fully vaccinated americans. let's get into all of it. let's bring in chief medical correspondent dr. sanjay gupta, and chief white house correspondent kaitlan collins. sanjay, the big headlines. basically if you're fully vaccinated, you can now enjoy, for the summer, lots of activities outdoors unmasked. but, not if you're in a big venue, basically like a concert or a stadium. l